1 citations
,
December 2024 in “Dermatology and Therapy” The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.
January 2021 in “Turkiye Klinikleri Journal of Dermatology” The MPV/PC ratio can help assess disease activity in alopecia areata.
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
29 citations
,
November 2018 in “Journal of The European Academy of Dermatology and Venereology” Personality traits and anxiety affect hair loss patients' quality of life.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
January 2021 in “Online Publication Service of Würzburg University (Würzburg University)” Diphenylcyclopropenon treatment for Alopecia areata is effective and safe, improving patients' quality of life.
218 citations
,
April 2012 in “British Journal of Dermatology” Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
21 citations
,
June 2017 in “Journal of The American Academy of Dermatology” Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.
16 citations
,
August 2003 in “Journal of The American Academy of Dermatology” Nitrogen mustard was not very effective for hair regrowth in alopecia areata and has potential skin cancer risk.
2 citations
,
October 2023 in “Dermatology and therapy” Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
1 citations
,
March 2025 in “Frontiers in Physiology” Methotrexate, resveratrol, and curcumin may help treat alopecia areata by targeting immune cells.
1 citations
,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
July 2023 in “Dermatology and therapy” People with alopecia areata may have a higher risk of blood clots.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
13 citations
,
January 2022 in “Advances in Dermatology and Allergology” Alopecia areata may be linked to imbalanced gut bacteria.
3 citations
,
November 2009 in “BMC dermatology” Dermatologists' treatment of alopecia areata is inconsistent, especially for children and advanced stages.
2 citations
,
January 2024 in “Journal of Emerging Investigators” A new algorithm effectively classifies Alopecia Areata, aiding early detection and treatment.
1 citations
,
January 2020 in “Benha Journal of Applied Sciences” Certain gene variations may increase the risk and severity of alopecia areata.
September 2025 in “Tạp chí Da liễu học Việt Nam” Combining oral methylprednisolone with microneedle radiofrequency improves hair growth in alopecia areata but may cause pain and side effects.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations
,
October 2021 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for severe alopecia areata show promise but lack standard approval.
27 citations
,
September 2014 in “JAMA dermatology” Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.
June 2023 in “Dermatology and therapy” The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.
85 citations
,
October 2012 in “Dermatologic Clinics” Alopecia Areata is an autoimmune condition often starting before age 20, with varied treatment success and a need for personalized treatment plans.
77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.